# Nephron commits to over $400M in 10-year syringe purchases from Sharps Technology

Nephron Pharmaceuticals committed to minimum orders of over $400 million over 10 years from Sharps Technology, starting with about $30 million of revenue in the first year, with product delivery scheduled for Q1 2024.

- Type: Contract
- Announced: 2023-09-26
- Where: United States
- Value: $400.0M
- Status: announced
- Products: copolymer prefillable syringe systems
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Sharps Technology](https://endata.com/companies/11050.md) (supplier)
- [Nephron Pharmaceuticals](https://endata.com/companies/11051.md) (customer)

## Sources

- [globenewswire.com](https://www.globenewswire.com/news-release/2023/09/26/2749524/0/en/Sharps-Technology-Signs-Asset-Purchase-Agreement-to-Acquire-InjectEZ-Specialty-Copolymer-Syringe-Manufacturing-Facility-and-a-10-Year-Purchase-Agreement-for-Over-400-Million-from-N.html), 2023-09-26: "Nephron commits to minimum orders of over $400 Million over 10 years; $30 Million in revenue the first year"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.